Asset comparator
Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.
- WuXi Biologics (Cayman) Inc.
- Novo Nordisk
Comparative performance (base 100)
Each asset is worth 100 at October 13, 2025; a value of 120 means +20% since that date (latest common date: October 9, 2026).
Each performance is calculated in the asset's trading currency, without currency conversion.
Indicators
"Not applicable" indicates a metric that has no meaning for this type of asset: it should not be compared.
| Indicator | WuXi Biologics (Cayman) Inc.Stock | Novo NordiskStock |
|---|---|---|
| Performance and risk | ||
| Performance over the periodChange in price between the first and last common dates. | +49.3% | −31.7% |
| Annualized performanceAverage annual return that would produce the same total performance. | +50.0% | −32.0% |
| Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates. | 44.6% | 48.4% |
| Maximum DrawdownLargest decline from peak to subsequent trough over the period. | −28.7% | −43.1% |
| Sharpe RatioReturn achieved above the risk-free rate (5.24%), per unit of volatility. The higher it is, the better risk was rewarded over the period. | 1.43 | -0.62 |
| 1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR). | −4.5% | −4.3% |
| Fundamentals | ||
| Market capitalizationTotal market value of all shares (or circulating tokens for a crypto). | 216.72B HKD | 1.13T DKK |
| P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid. | 39.6 | 9.8 |
| Price-to-SalesMarket capitalization divided by annual revenue. | 9.2 | 3.4 |
| Net marginShare of revenue retained as profit. | 21.2% | 35.3% |
| Return on equityReturn on equity (ROE). | 11.4% | 59.8% |
| Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year. | +18.4% | +2.1% |
| Dividend yieldAnnual dividend relative to the share price. | None | 4.68% |
| Debt / equityFinancial debt relative to shareholders' equity. | 5% | 63% |
Correlations over the period
From −1 to 1: close to 1, the two assets rise and fall together; close to 0, they move independently.
- WuXi Biologics (Cayman) Inc. / Novo Nordisk0.08
Information provided for educational purposes only. It does not constitute investment advice or a personalized recommendation. Past performance is no guarantee of future results.